MDxHealth SA is a Belgium-headquartered, commercial-stage precision diagnostics company listed on Nasdaq, focused on urologic and prostate-cancer tests such as ConfirmMDx, SelectMDx, and the ExoDx liquid-biopsy franchise. Its analyst coverage has been reset dramatically in 2026 as targets fell from as high as $9 earlier in the year.
The remaining verifiable targets on record span roughly $0.50 to $1.50. The most recent is Lake Street's $0.50 target, issued October 16, 2026, when analyst Thomas Flaten cut his figure from $3.00 and downgraded the stock to Hold. TD Cowen's $1.50 Buy target dates to May 14, 2026 and predates the October revenue miss, while one additional $1.00 target from mid-August remains on record. Averaging these three figures produces a mean of $1.00, which is used as the central target here. Importantly, this is not a well-populated consensus: BTIG withdrew its $2.00 target and moved to Neutral on October 19, and Craig-Hallum downgraded the stock to Hold without a price target on October 16. William Blair had earlier moved to Market Perform. The wide $0.50-to-$1.50 spread reflects genuine disagreement about whether the business can stabilize its sales force and rebuild growth.
Shares closed at $0.1393 on November 10, 2026, near the low end of a 52-week range of roughly $0.14 to $4.49. Reaching $1.00 from that level would require a gain of approximately 620%, a very large move by any standard. The path is complicated by the fact that the stock collapsed more than 60% in a single week in mid-October after the company pre-announced preliminary third-quarter revenue of $22.7 million, flat year over year and roughly 7.5% below consensus, and suspended its 2026 revenue guidance of $110 million to $115 million. Management attributed the shortfall to unexpected sales-force turnover following the wind-down of its former Resolve urinary-tract-infection test.
There are a few tangible supports. Liquid-based ExoDx test volume rose roughly 2.6-fold year over year in the third quarter, showing that the core prostate-diagnostic franchise retains demand. Second-quarter revenue grew 16% year over year and beat Wall Street estimates, and a $20 million registered direct placement in August extended the cash runway, leaving about $31.7 million in cash at September 30. Because $1.00 is the Nasdaq minimum-bid compliance level, a reverse split or renewed revenue momentum could mechanically or fundamentally restore the share price toward that threshold, although a reverse split creates no value on its own.
The obstacles are substantial. Tissue-based ConfirmMDx and GPS test volume fell 11% year over year, sales-force attrition disrupted forecasting, and the company suspended guidance with less than three months left in the year. The balance sheet is strained: non-current borrowings were about $96.4 million at mid-2026 against a market capitalization of roughly $13 million, with negative total equity. The company received a Nasdaq minimum-bid notice on July 2, 2026, and faces a compliance deadline around late December 2026. An earlier $10.4 million Medicare recoupment dispute and the exit from the Resolve business add further uncertainty, and any additional equity financing could dilute shareholders.
The $1.00 mark functions as a powerful psychological and regulatory level: it is both the Nasdaq minimum-bid compliance threshold and a former price zone now far above current trading. There is little meaningful near-term support beneath the recent 52-week low near $0.14, while resistance is layered between $0.50 and $1.00. The 52-week high near $4.49 underscores how far the stock has fallen, and the rapid October breakdown suggests the shares are in a state of distressed, high-volatility trading rather than an established uptrend.
Analyst price targets generally reflect a research horizon of roughly 12 months, but for MDXH the more urgent clock is regulatory: the Nasdaq cure period runs to approximately late December 2026. Investors should watch the third-quarter earnings report scheduled for November 12, 2026, any restoration of forward guidance, evidence that sales-force attrition has stopped, ExoDx and tissue-test volume trends, covenant compliance and cash burn, and any reverse-split or financing announcements.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, low-priced name like MDXH, such signals can help traders spot shifting momentum and monitor positions more efficiently than manual chart review. Traders can use the tool to discover new opportunities, track existing positions, and identify emerging trends across the market.
Can MDXHealth reach $1.00? The question is meaningful partly because $1.00 is the average of the remaining analyst targets ($0.50 to $1.50) and partly because it is the Nasdaq compliance threshold the company must ultimately clear. Reaching it from near $0.14 would require a very large, roughly 620% gain, and the near-term catalysts are heavily weighted toward risk: a revenue miss, withdrawn guidance, sales-force disruption, a leveraged balance sheet, and delisting pressure. The bull case rests on ExoDx volume growth and a stabilized cash position, but with several firms having withdrawn targets entirely, the analyst range is wide and conviction is low. Investors should monitor the November earnings report, guidance, and Nasdaq compliance developments rather than assume any particular outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that MDXH and ADPT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDXH and ADPT's prices will move in lockstep.
| Ticker / NAME | Correlation To MDXH | 1D Price Change % | ||
|---|---|---|---|---|
| MDXH | 100% | -11.78% | ||
| ADPT - MDXH | 29% Poorly correlated | -2.97% | ||
| BNGO - MDXH | 28% Poorly correlated | +6.03% | ||
| IRIX - MDXH | 27% Poorly correlated | -0.72% | ||
| CLPT - MDXH | 25% Poorly correlated | -4.36% | ||
| ICLR - MDXH | 24% Poorly correlated | -1.43% | ||
More | ||||